Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, and improved data quality. Before the COVID-19 pandemic, there was significant information on DCT benefits but only a few pilots, as enterprises grappled with regulatory uncertainties, upfront capital investment in sensors and products, and limited functionalities to decentralize clinical trials. In recent times, DCTs have proved to be a saving grace to restart paused clinical trials. The top reason for shifting to this model is that their patient-centered focus makes it easier for more people from a broader geographic spread to participate in trials without the need to visit a site.

Numerous start-ups that address DCT requirements have recently emerged. The landscape has also experienced heavy fundraising and M&A activity. Through co-innovation, continuous product improvements, and market education, DCT vendors are focusing on increasing trust, speeding trial timelines, and delivering a smooth experience in running DCTs.

In this report, we present Everest Group’s view of an end-to-end unified DCT platform and deep dive into the state of DCT adoption, the DCT vendor landscape, enterprise view of DCT vendors, challenges to adoption, and the future of decentralized trials.

Scope

Industry: life sciences

Geography: global

Contents

This report studies:

• Decentralized clinical trials adoption
• Everest Group’s view of an end-to-end unified DCT platform
• The DCT vendor landscape and focus areas for enterprises
• Challenges to DCT adoption and the future of DCTs

Membership(s)

Life Sciences Information Technology

Sourcing and Vendor Management